BPC-157 vs. TB-500
A neutral comparison of two recovery-category peptides — their regulatory status and how access differs across telehealth providers. Not a claim about what either does.
By The Peptide Samples Desk · 6 min read · Updated 2026-06-14
Find your match.
Answer two quick questions — we'll point you to the gummy that fits and this week's best deal.
BPC-157 and TB-500 are the two compounds people most often weigh against each other in the recovery category. This comparison sticks to what's actually verifiable: how each is categorized, their regulatory status, and how access differs across the providers we list.
We make no claim about what either peptide does, whether it works, or which is 'better.' Both sit in a gray regulatory area — neither is an FDA-approved finished drug — and that status matters more than any marketing.
For adults 18+. This article is educational and is not medical advice. Neither compound is an FDA-approved finished product; availability and legality vary, and quality outside a licensed provider is unverifiable. Statements have not been evaluated by the FDA.
The short version
- Both BPC-157 and TB-500 are commonly grouped as 'recovery' peptides, and neither is an FDA-approved finished drug.
- BPC-157 has drawn specific FDA attention and its availability through compounding pharmacies has narrowed; TB-500 (thymosin beta-4) sits in a similar unapproved, gray-market lane.
- Where they appear at all, it's inside lab-first, clinician-supervised programs (e.g. Marek, Defy, Invigor) — not as fast over-the-counter items.
- Gray-market 'research only / not for human consumption' versions sold online are unregulated, unverified for identity or purity, and carry real risk — see our research-vs-prescribed explainer.
- We make no efficacy or safety claim about either — that's a clinical judgment, and the regulatory status is the headline.
| Factor | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Category | Recovery/tissue-category peptide | Recovery/tissue-category peptide |
| FDA status | Not an FDA-approved finished drug; flagged by FDA, compounding access narrowed | Not an FDA-approved finished drug; unapproved |
| Typical legitimate access | Only via a licensed clinician, where available | Only via a licensed clinician, where available |
| Where it appears | Lab-first clinics (Marek, Defy, Invigor), where offered | Lab-first clinics, where offered |
| Gray-market form | Widely sold as 'research only' — unregulated, risky | Widely sold as 'research only' — unregulated, risky |
| Over-the-counter? | No compliant OTC version | No compliant OTC version |
BPC-157 vs. TB-500, on category, status, and access — facts and access paths, not effects. Verify current availability with each provider.
Find your match
30-sec finder
Question 1 of 5
What are you here to look into?
Same gray area, status is the headline
Both BPC-157 and TB-500 are commonly marketed in the recovery category, and the most important fact about each is the same: neither is an FDA-approved finished drug. BPC-157 in particular has drawn explicit FDA attention, and its availability through compounding pharmacies has narrowed as a result. TB-500 (thymosin beta-4) sits in a comparable unapproved lane. We don't describe what either does — only that they share a category and an unapproved status.
The real difference for a reader: access and risk
Because of that status, neither shows up as a fast, low-commitment menu item the way sermorelin does. Where they appear at all, it's inside the lab-first, clinician-supervised programs at clinics like Marek Health, Defy Medical, and Invigor Medical — and only where currently permitted. The far more common way these are sold online is the gray market: vials labeled 'for research use only, not for human consumption.' Those are unregulated, not verified for identity or purity, and carry real risk. We cover that distinction in research peptides vs. prescribed.
How to think about it
This isn't a 'which is better' question — we make no claim about effects, and the appropriateness of either is a clinical decision. If you're exploring the recovery category, the responsible path is a conversation with a licensed provider who can tell you what's currently legal, available, and appropriate, rather than ordering an unverified vial online. Start with our where to get BPC-157 from a licensed provider guide.
Questions, answered
What's the difference between BPC-157 and TB-500?
Both are commonly grouped as recovery-category peptides, and neither is an FDA-approved finished drug. We make no claim about what either does or which is 'better.' The practical difference for a reader is that both are hard to access legitimately — where offered at all, it's inside lab-first clinician-supervised programs. This is educational, not medical advice.
Are BPC-157 and TB-500 legal?
Neither is an FDA-approved finished product, and BPC-157 has specifically drawn FDA attention that narrowed compounding-pharmacy access. Legality and availability vary and change over time. Gray-market 'research only' versions are unregulated. Confirm current status with a licensed provider.
Can I buy them over the counter?
There is no compliant over-the-counter version of either. The 'research only / not for human consumption' vials sold online are unregulated and not verified for identity or purity. A licensed clinician is the only legitimate path, where these are available at all.
Which is safer or more effective?
We don't make safety or efficacy claims about either compound — that's a clinical judgment, and neither is FDA-approved. The regulatory status and sourcing risk are the headline. Statements have not been evaluated by the FDA.